Dalbavancin Injection 500 mg Single-Dose Powder Vial, Sterile (RX)
#1 Dalbavancin Injection 500 mg – Sterile Single-Dose Powder Vial | Powerful Antibiotic for Serious Skin Infections | By Meitheal Pharmaceuticals | NDC: 71288-0034-50
Best-in-Class Treatment for Serious Bacterial Infections – Hospital-Grade Dalbavancin 500 mg
Experience next-level infection control with Dalbavancin Injection 500 mg Single-Dose Powder Vial, Sterile by Meitheal Pharmaceuticals. This advanced, FDA-approved antibiotic injection is formulated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI), including life-threatening cand resistant Gram-positive pathogens. Designed for healthcare settings, this sterile powder vial delivers the trusted efficacy, safety, and convenience practitioners demand.
Indications:
- Cellulitis
- Abscesses
- Wound infections
- Skin and soft tissue infections
How Dalbavancin Stands Out:
- Long half-life—single or two-dose option
- Compatible for reconstitution and IV infusion
- Excellent safety and tolerability
- Better outcomes for complicated skin infections
⭐ Why Choose Dalbavancin Injection 500 mg by Meitheal Pharmaceuticals?
- Potent, Once-Weekly IV Antibiotic: Ideal for hospital and outpatient use—provides convenient dosing with just one or two infusions.
- Broad-Spectrum Gram-Positive Coverage: Highly effective against MRSA, MSSA, Streptococcus pyogenes, and other resistant pathogens causing complicated skin infections.
- FDA-Approved for ABSSSI: Clinically proven in treating serious skin and soft tissue infections.
- Sterile Powder Vial for Injection: Ensures maximum stability, purity, and safe reconstitution for intravenous administration.
- Trusted by Hospitals & Healthcare Systems Nationwide: Manufactured to strict cGMP standards for consistent, reliable clinical results.
- Minimizes Hospital Stays: Enables outpatient therapy and rapid discharge, helping reduce hospital-acquired infection risks and costs.
Dalbavancin is a cutting-edge, long-acting lipoglycopeptide antibiotic indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and pediatric patients. Its unique pharmacokinetics allow for single or two-dose IV regimens, providing:
- Rapid and sustained bacterial clearance
- Superior activity against multidrug-resistant bacteria including MRSA (methicillin-resistant Staphylococcus aureus)
- Decreased need for prolonged inpatient care or daily infusions
- Enhanced patient compliance and minimized risk of reinfection
